Protea Biosciences Group, Inc. has purchased vivoPharm Pty Ltd., a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models. With facilities in Melbourne, Australia and Hershey, PA, along with a sales office in Munich, Germany, upon completion of the acquisition vivoPharm will operate as a business unit of Protea. Protea’s chairman and chief executive officer, Stephen Turner said, “The combined company will...